AVXL (Anavex Life Sciences) Other Current Liabilities: $1.23 Mil (As of Dec. 2025)


AVXL Anavex Life Sciences Corp AVXL
30 GF Score
Price $2.72
! 1 Warning Sign
View Full Analysis

What is Anavex Life Sciences Other Current Liabilities?

Anavex Life Sciences AVXL -0.74% 30 Other Current Liabilities is $1.23 Mil as of Dec. 2025. GuruFocus rates AVXL with a GF Score™ of 30/100. The stock has 1 warning sign investors should review.

Anavex Life Sciences's other current liabilities for the quarter that ended in Dec. 2025 was $1.23 Mil.

Anavex Life Sciences's quarterly other current liabilities increased from Jun. 2025 ($1.19 Mil) to Sep. 2025 ($1.56 Mil) but then declined from Sep. 2025 ($1.56 Mil) to Dec. 2025 ($1.23 Mil).

Anavex Life Sciences's annual other current liabilities increased from Sep. 2023 ($1.36 Mil) to Sep. 2024 ($1.53 Mil) and increased from Sep. 2024 ($1.53 Mil) to Sep. 2025 ($1.56 Mil).

Anavex Life Sciences Other Current Liabilities Related Terms

Anavex Life Sciences Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Anavex Life Sciences's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anavex Life Sciences Other Current Liabilities Chart

Anavex Life Sciences Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.20 1.30 1.36 1.53 1.56

Anavex Life Sciences Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.02 2.20 1.19 1.56 1.23
AVXL
30GF Score
Anavex Life Sciences Corp AVXL
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Anavex Life Sciences Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of $1.23 Mil mean?
Anavex Life Sciences (AVXL) has a Other Current Liabilities of $1.23 Mil as of Dec. 2025. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Anavex Life Sciences.
Is Anavex Life Sciences' Other Current Liabilities too high?
Anavex Life Sciences' current Other Current Liabilities is $1.23 Mil. Overall, Anavex Life Sciences has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Anavex Life Sciences' Other Current Liabilities compare to SLGL and FATE?
Anavex Life Sciences' Other Current Liabilities of $1.23 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Biotechnology company?
A good Other Current Liabilities depends on the Biotechnology industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Anavex Life Sciences. Anavex Life Sciences's current Other Current Liabilities is $1.23 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anavex Life Sciences stock overvalued right now?
Anavex Life Sciences (AVXL) has a current Other Current Liabilities of $1.23 Mil. The current Other Current Liabilities is $1.23 Mil. Anavex Life Sciences' overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Anavex Life Sciences (AVXL), the current Other Current Liabilities is $1.23 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Anavex Life Sciences Business Description

Other Exchanges 0HFR:UK12X1:Germany
Address 630 5th Avenue, 20th Floor, New York, NY, USA, 10111
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.
30GF Score

Get the complete analysis for AVXL

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.72
Price